(Q45998750)

18 December 2017

title

High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study. (English)

1 reference

18 December 2017

1 reference

8

1 reference

18 December 2017

author name string

A Millonig

1

1 reference

18 December 2017

D Rudzki

2

1 reference

18 December 2017

M Hölzl

3

1 reference

18 December 2017

R Ehling

4

1 reference

18 December 2017

C Gneiss

5

1 reference

18 December 2017

B Künz

6

1 reference

18 December 2017

T Berger

7

1 reference

18 December 2017

F Deisenhammer

9

1 reference

18 December 2017

publication date

22 May 2009

1 reference

18 December 2017

Multiple Sclerosis Journal

published in

1 reference

18 December 2017

volume

15

1 reference

18 December 2017

issue

8

1 reference

18 December 2017

page(s)

977-983

1 reference

18 December 2017

Human immune response to recombinant human proteins

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Bioequivalence and the immunogenicity of biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Assessment of the antigenic response in humans to a recombinant mutant interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

An Analysis of Neutralization Reaction of Interferon by Antibody: A Proposal on the Expression of Neutralization Titer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Biological and clinical effects of interferon-beta ser at two doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509105384

21 January 2018

Identifiers

DOI

10.1177/1352458509105384

1 reference

18 December 2017

1 reference

18 December 2017